Research location

Newmarket

Ontario, Canada

Published trials230

Site observations239

Linked trials published230

Page1 / 5

Research activity in Newmarket

Ontario, Canada

CureCurrent currently publishes aggregate city-level research activity for this location: 230 trials and 239 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Newmarket

230 linked trials · page 1 of 5

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

Ted Rogers Understanding of Exacerbations in Heart Failure 2: MonitorNCT07447908 · 2026-06-16 · 1 site observation

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InNCT06745908 · 2025-10-01 · 1 site observation

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation

Alleviant ALLAY-HFrEF StudyNCT06812533 · 2025-03-10 · 1 site observation

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287 · 2025-02-04 · 1 site observation

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04 · 1 site observation

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation

RAFT - Pace &AblateNCT06299514 · 2024-04-25 · 1 site observation

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)NCT05417516 · 2023-11-20 · 1 site observation

Left vs Left Randomized Clinical TrialNCT05650658 · 2023-09-13 · 1 site observation

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)NCT05427370 · 2023-06-22 · 1 site observation

Alleviant ALLAY-HF StudyNCT05685303 · 2023-01-10 · 1 site observation

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT06034743 · 2023-11-22 · 1 site observation

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · 2023-02-06 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)NCT05592275 · 2023-02-03 · 1 site observation

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyNCT05450692 · 2022-09-15 · 1 site observation

ACTIVE_NOT_RECRUITING

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22 · 1 site observation

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%NCT04986202 · 2021-06-30 · 1 site observation

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)NCT04894591 · 2021-06-28 · 1 site observation

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470 · 2021-06-15 · 1 site observation

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesityNCT04788511 · 2021-03-16 · 1 site observation

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04760626 · 2021-03-01 · 1 site observation

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorNCT04650581 · 2021-01-27 · 1 site observation

ACTIVE_NOT_RECRUITING

Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715 · 2020-12-31 · 1 site observation

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)NCT04509674 · 2020-12-16 · 1 site observation

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)NCT04609878 · 2020-12-15 · 1 site observation

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate CancerNCT04549207 · 2020-10-09 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19 · 1 site observation

ACTIVE_NOT_RECRUITING

Durvalumab Long-Term Safety and Efficacy StudyNCT04078152 · 2019-09-05 · 1 site observation

Prostate Margin Reduction to Reduce Acute Rectal Toxicity (PROTRACT)NCT04004858 · 2019-08-01 · 1 site observation

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)NCT03976323 · 2019-06-28 · 1 site observation

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)NCT03976362 · 2019-06-28 · 1 site observation

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)NCT03888066 · 2019-04-24 · 1 site observation

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibNCT03778229 · 2019-01-09 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsNCT03836352 · 2018-12-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaNCT03769090 · 2018-12-13 · 1 site observation

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)NCT03664687 · 2018-10-31 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.